KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash from Financing Activities (2017 - 2025)

Twist Bioscience (TWST) has disclosed Cash from Financing Activities for 7 consecutive years, with $442000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Cash from Financing Activities fell 64.35% to $442000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $911000.0, a 99.66% decrease, with the full-year FY2025 number at $28.5 million, up 314.22% from a year prior.
  • Cash from Financing Activities was $442000.0 for Q3 2023 at Twist Bioscience, up from -$661000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $326.9 million in Q4 2020 to a low of -$1.6 million in Q1 2019.
  • A 5-year average of $52.1 million and a median of $1.5 million in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 102.98% in 2019, then soared 18619.23% in 2022.
  • Twist Bioscience's Cash from Financing Activities stood at $2.1 million in 2019, then soared by 15793.1% to $326.9 million in 2020, then tumbled by 100.31% to -$1.0 million in 2021, then skyrocketed by 60.93% to -$395000.0 in 2022, then skyrocketed by 211.9% to $442000.0 in 2023.
  • Per Business Quant, the three most recent readings for TWST's Cash from Financing Activities are $442000.0 (Q3 2023), -$661000.0 (Q2 2023), and $1.5 million (Q1 2023).